Compare Abbott Laboratories (ABT) vs American States Water Company (AWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs American States Water Company — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while American States Water Company trades at $83.47 (market cap $3.26B). The key difference: Abbott Laboratories is far larger — about 51.2× American States Water Company's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | AWR | |
|---|---|---|
Market Cap | $166.94B | $3.26B |
Sector | Health | Utilities |
52-Week High | $136.62 | $84.76 |
52-Week Low | $82.57 | $70.10 |
Enterprise Value | $193.69B | $4.17B |
Dividend Yield | 2.63% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
American States Water (AWR) trades at $83.14, down 1.91% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.66% net margins and consistent dividend growth, though recent earnings show mixed quarterly performance. Recent news highlights AWR's defensive utility characteristics and completion of a $200 million equity offering program.
AWR presents a stable investment case with reliable dividend income and utility sector defensiveness, though valuation appears elevated at 24.24 P/E. Key risks include regulatory rate pressures and execution of capital investments. Analyst sentiment remains cautious with only 20% buy ratings, suggesting limited near-term upside potential despite the company's operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
